ATE540037T1 - Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten - Google Patents

Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten

Info

Publication number
ATE540037T1
ATE540037T1 AT08758202T AT08758202T ATE540037T1 AT E540037 T1 ATE540037 T1 AT E540037T1 AT 08758202 T AT08758202 T AT 08758202T AT 08758202 T AT08758202 T AT 08758202T AT E540037 T1 ATE540037 T1 AT E540037T1
Authority
AT
Austria
Prior art keywords
compounds
treatment
cycloalkyl
aryl
optionally substituted
Prior art date
Application number
AT08758202T
Other languages
English (en)
Inventor
Jakob Felding
Morten Syrensen
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Application granted granted Critical
Publication of ATE540037T1 publication Critical patent/ATE540037T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT08758202T 2007-04-16 2008-04-16 Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten ATE540037T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91202007P 2007-04-16 2007-04-16
PCT/DK2008/000135 WO2008125111A1 (en) 2007-04-16 2008-04-16 Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases

Publications (1)

Publication Number Publication Date
ATE540037T1 true ATE540037T1 (de) 2012-01-15

Family

ID=39539479

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08758202T ATE540037T1 (de) 2007-04-16 2008-04-16 Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten

Country Status (7)

Country Link
US (1) US8829190B2 (de)
EP (1) EP2146989B1 (de)
JP (1) JP2010523725A (de)
CN (1) CN101679428A (de)
AT (1) ATE540037T1 (de)
ES (1) ES2380395T3 (de)
WO (1) WO2008125111A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172206A1 (en) 2008-12-19 2011-07-28 Leo Pharma As Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
US8685967B2 (en) 2009-04-07 2014-04-01 Merck Sharp & Dohme Corp. Substituted triazolopyridines and analogs thereof
NZ597140A (en) 2009-06-05 2014-01-31 Cephalon Inc Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
WO2012121988A2 (en) 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
WO2013092739A1 (en) * 2011-12-21 2013-06-27 Leo Pharma A/S [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors
WO2014206903A1 (en) 2013-06-25 2014-12-31 Leo Pharma A/S METHODS FOR THE PREPARATION OF SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIDINES
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
NZ723203A (en) 2014-02-13 2020-08-28 Incyte Corp Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (de) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamine als lsd1-inhibitoren
KR102421235B1 (ko) 2014-02-13 2022-07-15 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
UA122688C2 (uk) 2015-04-03 2020-12-28 Інсайт Корпорейшн Гетероциклічні сполуки як інгібітори lsd1
JP7427363B2 (ja) 2015-08-12 2024-02-05 インサイト・ホールディングス・コーポレイション Ｌｓｄ１阻害剤の塩
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU705690B2 (en) 1995-05-19 1999-05-27 Kyowa Hakko Kogyo Co. Ltd. Oxygen-containing heterocyclic compounds
JP4373497B2 (ja) * 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
WO1998022455A1 (en) 1996-11-19 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Oxygenic heterocyclic compounds
JP2006517580A (ja) 2003-02-14 2006-07-27 ファイザー・プロダクツ・インク 抗炎症化合物としてのトリアゾロピリジン
MX2007004179A (es) * 2004-10-07 2007-06-07 Warner Lambert Co Derivados de triazolpiridina como agentes antibacterianos.

Also Published As

Publication number Publication date
CN101679428A (zh) 2010-03-24
US8829190B2 (en) 2014-09-09
JP2010523725A (ja) 2010-07-15
EP2146989B1 (de) 2012-01-04
US20100113442A1 (en) 2010-05-06
EP2146989A1 (de) 2010-01-27
WO2008125111A1 (en) 2008-10-23
ES2380395T3 (es) 2012-05-11

Similar Documents

Publication Publication Date Title
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
MY150075A (en) Novel phosphodiesterase inhibitors
MX2013012555A (es) Inhibidores novedosos de rock.
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
PH12012502572A1 (en) Novel nicotinamide derivative or salt thereof
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
WO2012007869A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
MA32460B1 (fr) Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
NZ610312A (en) 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors
AR083842A1 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a las angiogenesis
JO3121B1 (ar) مشتقات 1 - ((5-هيتيرورلثيازول-2-يل) أمينوكاربونيل) بيروليدين-2-كربوكساميد كمثبات الفوسفاتديلينوسيتول 3-كيناس (pi3k) مفيدة في علاج الأمراض التصاعدية
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
AR082968A1 (es) Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto
CA2897273C (en) Benzylamine derivatives
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
MX2009003227A (es) Moduladores de los receptores de glutamato metabotropicos 5(mglur5).
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
MD20150075A2 (ro) Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia